초록 ▼

A method of preparing a supramolecular complex containing at least one therapeutic agent and a multi-dimensional polymer network is described. A supramolecular complex prepared by a method of the invention is described. A method of treatment by administering a therapeutically effective amount of a s

A method of preparing a supramolecular complex containing at least one therapeutic agent and a multi-dimensional polymer network is described. A supramolecular complex prepared by a method of the invention is described. A method of treatment by administering a therapeutically effective amount of a supramolecular complex of the invention is also described. Such a supramolecular complex may be used as a delivery vehicle for various therapeutic agents.

대표청구항 ▼

The invention claimed is: 1. A method of preparing a supramolecular complex comprising: contacting a therapeutic agent and a substantially linear cyclodextrin-containing polymer to form a composite via a covalent bond, a non-covalent bond, a non-covalent interaction, or a combination thereof; and c

The invention claimed is: 1. A method of preparing a supramolecular complex comprising: contacting a therapeutic agent and a substantially linear cyclodextrin-containing polymer to form a composite via a covalent bond, a non-covalent bond, a non-covalent interaction, or a combination thereof; and covalently crosslinking said substantially linear cyclodextrin-containing polymer of said composite under conditions sufficient to form a supramolecular complex of a multi-dimensional polymer network-containing said therapeutic agent; wherein the cyclodextrin moieties within said substantially linear cyclodextrin-containing polymer are substituted or unsubstituted cyclodextrin moieties. 2. The method of claim 1, wherein said therapeutic agent is selected from an antibiotic, a steroid, a polynucleotide, a plasmid, a peptide, a peptide fragment, a small molecule, a chelating agent, a biologically active macromolecule, and a mixture thereof. 3. The method of claim 2, wherein said therapeutic agent is a polynucleotide. 4. The method of claim 2, wherein said therapeutic agent is a therapeutic agent comprising a ligand, whereby said ligand allows the therapeutic agent to target or bind to a cell. 5. The method of claim 4, wherein said ligand is selected from vitamins, proteins, and polysaccharides. 6. The method of claim 1, wherein said crosslinking agent is selected from adipic acid dihydrazide, polyethylene glycol 600 dihydrazide, dimethyl 3,3'-dithiobispropionimidate, dithiobis(succinimidyl propionate), disuccinimidyl suberate, and dimethylsuberimidate (DMS). 7. The method of claim 1, further comprising contacting said composite with a ligand to form a ligand-containing supramolecular complex, wherein said ligand allows said ligand-containing supramolecular complex to target or bind to a cell. 8. The method of claim 7, wherein said ligand is selected from vitamins, proteins, and polysaccharides. 9. The method of claim 1, further comprising contacting said supramolecular complex with a ligand to form a ligand-containing supramolecular complex, wherein said ligand allows said ligand-containing supramolecular complex to target or bind to a cell. 10. The method of claim 9, wherein said ligand is selected from vitamins, proteins, and polysaccharides. 11. A supramolecular complex prepared by the method of claim 1. 12. A method of delivering a therapeutic agent comprising administering, to a patient in need thereof, a therapeutically effective amount of a supramolecular complex of claim 11. 13. A supramolecular complex prepared by the method of claim 7. 14. A method of delivering a therapeutic agent comprising administering, to a patient in need thereof, a therapeutically effective amount of a supramolecular complex of claim 13. 15. A supramolecular complex prepared by the method of claim 9. 16. A method of delivering a therapeutic agent comprising administering, to a patient in need thereof, a therapeutically effective amount of a supramolecular complex of claim 15. 17. The method of claim 1, wherein said substantially linear cyclodextrin-containing polymer is a substantially linear cyclodextrin-containing copolymer having repeating units of formula Ia, Ib, or both: wherein C is a substituted or unsubstituted cyclodextrin monomer and A is a comonomer bound to cyclodextrin C. 18. A method of preparing a supramolecular complex comprising: contacting a therapeutic agent and a substantially linear oxidized cyclodextrin-containing polymer to form a composite via a covalent bond, a non-covalent bond, a non-covalent interaction, or a combination thereof; and covalently crosslinking said substantially linear oxidized cyclodextrin-containing polymer of said composite under conditions sufficient to form a supramolecular complex of a multidimensional polymer network containing said therapeutic agent; wherein the cyclodextrin moieties within said substantially linear oxidized cyclodextrin-containing polymer are substituted or unsubstituted oxidized cyclodextrin moieties. 19. The method of claim 18, wherein said therapeutic agent is selected from an antibiotic, a steroid, a polynucleotide, a plasmid, a peptide, a peptide fragment, a small molecule, a chelating agent, a biologically active macromolecule, and a mixture thereof. 20. The method of claim 19, wherein said therapeutic agent is DNA. 21. The method of claim 18, further comprising contacting said composite or said supramolecular complex with a ligand to form a ligand-containing supramolecular complex, wherein said ligand allows the ligand-containing supramolecular complex to target or bind to a cell. 22. The method of claim 21, wherein said ligand is selected from vitamins, proteins, and polysaccharides. 23. The method of claim 18, wherein said crosslinking agent is selected from adipic acid dihydrazide, polyethylene glycol 600 dihydrazide, dimethyl 3,3'-dithiobispropionimidate, dithiobis(succinimidyl propionate), disuccinimidyl suberate, and dimethylsuberimidate (DMS). 24. A supramolecular complex prepared by a method of claim 18. 25. A method of delivering a therapeutic agent comprising administering, to a patient in need thereof, a therapeutically effective amount of a supramolecular complex of claim 24. 26. A supramolecular complex prepared by a method of claim 21. 27. A method of delivering a therapeutic agent comprising administering, to a patient in need thereof, a therapeutically effective amount of a supramolecular complex of claim 26. 28. The method of claim 18, wherein said substantially linear oxidized cyclodextrin-containing polymer is a substantially linear oxidized cyclodextrin-containing copolymer having repeating units of formula VIa, VIb, or both: wherein C is a substituted or unsubstituted oxidized cyclodextrin monomer and A is a divalent comonomer bound to cyclodextrin C. 29. The method of claim 1, wherein said supramolecular complex is prepared in a form suitable for administration to a patient. 30. The method of claim 18, wherein said supramolecular complex is prepared in a form suitable for administration to a patient. 31. The method of claim 1, wherein the substantially linear cyclodextrin-containing polymer is crosslinked with the same species of polymer. 32. The method of claim 18, wherein the substantially linear oxidized cyclodextrin-containing polymer is crosslinked with the same species of polymer. 33. The method of claim 1, wherein the substantially linear cyclodextrin-containing polymer is crosslinked with a different species of polymer. 34. The method of claim 18, wherein the substantially linear oxidized cyclodextrin-containing polymer is crosslinked with a different species of polymer.